Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 10/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932666 | 1.00 | SMO (0.43) | SMOHSD11B1RECQLTACR1TACR3 | |
| SCHEMBL9968407 | 0.93 | HSD11B1 (0.41) | SMOHSD11B1MEN1KMT2A | |
| SCHEMBL9968393 | 0.93 | HSD11B1 (0.41) | SMOHSD11B1MEN1KMT2A | |
| SCHEMBL9931928 | 0.85 | SMO (0.43) | SMOHSD11B1SUV39H2MEN1KMT2A | |
| SCHEMBL9932918 | 0.85 | SMO (0.43) | SMOHSD11B1SUV39H2MEN1KMT2A | |
| SCHEMBL9932631 | 0.85 | SMO (0.59) | SMOHSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL9968396 | 0.84 | CXCR3 (0.40) | SMOHSD11B1MEN1KMT2A | |
| SCHEMBL9968405 | 0.84 | CXCR3 (0.40) | SMOHSD11B1MEN1KMT2A | |
| SCHEMBL9932524 | 0.83 | SMO (0.51) | SMOHSD11B1 | |
| SCHEMBL9932004 | 0.82 | SMO (0.43) | SMOHSD11B1SUV39H2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885HSD11B1 3610/4885RECQL 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.